Replimune Group, Inc.
REPL · XNASCIK 1737953fmd_1Q7JQ0GWZ3DZAEB25N5MNTAV1FManufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Apr 01, 2016 to Sep 30, 2026, 39 periods
| Line item | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | 7 | 14 | 22 | 39 | 57 | 80 | 127 | 175 | 189 | 221 |
| Selling, general and administrative | – | – | – | – | – | – | – | – | 72 | 99 |
| Total operating expenses | 10 | 19 | 31 | 56 | 80 | 118 | 177 | 235 | 262 | 320 |
| Operating income | (10) | (19) | (31) | (56) | (80) | (118) | (177) | (235) | (262) | (320) |
| Interest expense | – | – | – | 1 | 1 | 0 | 2 | 4 | 6 | 7 |
| Interest and investment income | 0 | 0 | 3 | 2 | 1 | 0 | 10 | 23 | 21 | 14 |
| Other non-operating income (expense) | 2 | (0) | 0 | 4 | (1) | 0 | 3 | 19 | 15 | 5 |
| Income before taxes | (8) | (20) | (31) | (53) | (81) | (118) | (174) | (215) | (247) | (314) |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | (1) |
| Net income from continuing operations | (8) | (20) | (31) | (53) | (81) | (118) | (174) | (215) | (247) | (314) |
| Net income | (8) | (20) | (31) | (53) | (81) | (118) | (174) | (216) | (247) | (314) |
| Net income to common shareholders | (8) | (20) | (31) | (53) | (81) | (118) | (174) | (216) | (247) | (314) |